Reaction
Transitional Cell Carcinoma reporting signals
As of the last recalculation, Transitional Cell Carcinoma appears in 1,282 FAERS reports alongside 32 co-occurring drug terms. The strongest observed disproportionality signal is SIROLIMUS (PRR 52.3).
Important: FAERS is a spontaneous, voluntary, unverified reporting system. PRR and ROR identify reporting patterns for investigation; they are not incidence rates and do not establish causation.
| Drug | Co-reports | PRR | ROR |
|---|---|---|---|
| Sirolimus | 42 | 52.3 | 52.5 |
| Anti-Thymocyte Globulin (Rabbit) | 14 | 28.5 | 28.5 |
| Mycophenilic Acid | 30 | 24.0 | 24.1 |
| Pioglitazone | 56 | 21.9 | 22.0 |
| Everolimus Tablets | 22 | 21.7 | 21.7 |
| Basiliximab | 15 | 20.9 | 21.0 |
| Mycophenolic Acid | 35 | 18.2 | 18.2 |
| Tacrolimus Ointment 0.1% | 126 | 18.1 | 18.1 |
| Tacrolimus Extended-Release Capsules | 126 | 18.1 | 18.1 |
| Cisplatin | 77 | 17.0 | 17.0 |
| Tacrolimus | 136 | 15.7 | 15.7 |
| Gemcitabine | 33 | 13.9 | 13.9 |
| Mycophenolate Mofetil | 107 | 13.9 | 13.9 |
| Mycophenolate Mofetil Hydrochloride | 107 | 13.8 | 13.8 |
| Terazosin Hydrochloride | 7 | 12.8 | 12.9 |
| Melphalan Hydrochloride | 19 | 12.5 | 12.5 |
| Melphalan | 17 | 12.3 | 12.3 |
| Gemcitabine Hydrochloride | 37 | 11.6 | 11.6 |
| Selinexor | 6 | 11.3 | 11.3 |
| Doxorubicin | 53 | 10.0 | 10.0 |
| Baricitinib | 5 | 8.4 | 8.5 |
| Fludarabine Phosphate | 20 | 8.4 | 8.4 |
| Vemurafenib | 6 | 8.1 | 8.1 |
| Pemetrexed | 10 | 7.6 | 7.6 |
| Pegfilgrastim | 40 | 6.8 | 6.8 |
| Daratumumab | 16 | 6.6 | 6.6 |
| Abiraterone | 5 | 6.0 | 6.0 |
| Obinutuzumab | 6 | 5.9 | 5.9 |
| Ranitidine Hydrochloride | 17 | 5.1 | 5.1 |
| Enzalutamide | 14 | 3.9 | 3.9 |
| Ixekizumab | 7 | 3.1 | 3.1 |
| Guselkumab | 6 | 2.7 | 2.7 |